Tianjin Lisheng Pharmaceutical Company Ltd., a subsidiary of TIANJIN DEV (00882), announced its first-quarter 2026 financial results. The company recorded operating revenue of approximately 332 million yuan, representing a year-on-year decrease of 10.16%. Net profit attributable to owners of the parent company was about 51.883 million yuan, down 6.14% compared to the same period last year. Basic earnings per share stood at 0.2 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments